1. Home
  2. AL vs TGTX Comparison

AL vs TGTX Comparison

Compare AL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AL
  • TGTX
  • Stock Information
  • Founded
  • AL 2010
  • TGTX 1993
  • Country
  • AL United States
  • TGTX United States
  • Employees
  • AL N/A
  • TGTX N/A
  • Industry
  • AL Diversified Commercial Services
  • TGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AL Consumer Discretionary
  • TGTX Health Care
  • Exchange
  • AL Nasdaq
  • TGTX Nasdaq
  • Market Cap
  • AL 7.1B
  • TGTX 4.2B
  • IPO Year
  • AL 2011
  • TGTX 1995
  • Fundamental
  • Price
  • AL $63.55
  • TGTX $32.48
  • Analyst Decision
  • AL Buy
  • TGTX Strong Buy
  • Analyst Count
  • AL 5
  • TGTX 5
  • Target Price
  • AL $61.40
  • TGTX $45.00
  • AVG Volume (30 Days)
  • AL 3.0M
  • TGTX 2.1M
  • Earning Date
  • AL 11-06-2025
  • TGTX 11-03-2025
  • Dividend Yield
  • AL 1.38%
  • TGTX N/A
  • EPS Growth
  • AL 76.97
  • TGTX N/A
  • EPS
  • AL 8.24
  • TGTX 0.36
  • Revenue
  • AL $2,873,037,000.00
  • TGTX $454,069,000.00
  • Revenue This Year
  • AL $11.13
  • TGTX $82.58
  • Revenue Next Year
  • AL $6.32
  • TGTX $44.99
  • P/E Ratio
  • AL $7.71
  • TGTX $88.81
  • Revenue Growth
  • AL 6.15
  • TGTX 30.96
  • 52 Week Low
  • AL $38.25
  • TGTX $21.16
  • 52 Week High
  • AL $64.30
  • TGTX $46.48
  • Technical
  • Relative Strength Index (RSI)
  • AL 70.50
  • TGTX 59.33
  • Support Level
  • AL $63.38
  • TGTX $31.29
  • Resistance Level
  • AL $63.70
  • TGTX $33.33
  • Average True Range (ATR)
  • AL 0.28
  • TGTX 1.16
  • MACD
  • AL -0.09
  • TGTX 0.30
  • Stochastic Oscillator
  • AL 83.03
  • TGTX 80.71

About AL Air Lease Corporation

Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in purchasing commercial jet aircrafts directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a majority of its revenue from the Asia-Pacific region and the rest from Europe, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: